Studies in animal models of AD have shown that treatment with DPP-4 inhibitors (such as saxagliptin, vildagliptin, linagliptin, and sitagliptin) increases GLP-1 expression in the hippocampus and other various brain regions (88–91). This evidence concerns the gene GLP1R and Alzheimer disease.